🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,57 USD

Máx. histórico

178,74

2144 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,17%

Rango 52 semanas

14,68 – 24,68

Variación hoy

-7,48%

Cierre anterior

18,99

Rango de hoy

17,44 – 18,92

Volumen hoy

1.859.162

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 15 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/10/2003 30,00 30,30 28,80 29,04 -2,02% 5,00% 38.967
29/10/2003 29,10 30,00 28,80 29,64 -2,76% 4,12% 46.300
28/10/2003 30,66 31,02 30,24 30,48 -1,74% 2,54% 24.617
27/10/2003 30,00 31,20 29,94 31,02 +4,02% 4,20% 33.217
24/10/2003 28,80 30,84 28,62 29,82 +3,97% 7,71% 57.000
23/10/2003 29,10 30,00 28,50 28,68 -3,43% 5,15% 37.700
22/10/2003 30,60 30,66 29,46 29,70 -3,32% 3,92% 27.217
21/10/2003 29,88 30,72 29,88 30,72 +4,70% 2,81% 34.983
20/10/2003 29,64 30,00 28,80 29,34 -1,21% 4,05% 34.683
17/10/2003 30,84 31,20 29,22 29,70 -3,13% 6,42% 63.100
16/10/2003 31,20 31,80 30,66 30,66 -2,11% 3,65% 42.217
15/10/2003 31,86 32,46 30,66 31,32 -3,15% 5,65% 56.467
14/10/2003 32,52 32,70 31,92 32,34 -0,55% 2,40% 28.667
13/10/2003 32,76 33,00 32,40 32,52 -1,45% 1,83% 15.467
10/10/2003 32,52 33,48 31,86 33,00 +2,04% 4,98% 33.583
09/10/2003 32,34 33,54 31,80 32,34 +1,13% 5,38% 51.200
08/10/2003 32,70 32,70 31,50 31,98 +1,14% 3,67% 36.017
07/10/2003 30,60 31,74 30,60 31,62 +3,33% 3,73% 34.933
06/10/2003 31,38 31,50 30,42 30,60 -2,49% 3,44% 23.750
03/10/2003 31,02 32,16 30,60 31,38 +1,55% 5,03% 35.600
02/10/2003 30,90 31,08 30,30 30,90 +0,00% 2,52% 23.017
01/10/2003 30,90 31,50 30,36 30,90 -0,39% 3,69% 30.067
30/09/2003 31,80 32,40 30,78 31,02 -2,82% 5,09% 41.500
29/09/2003 31,32 32,10 31,20 31,92 +2,11% 2,87% 25.717
26/09/2003 32,04 32,28 30,30 31,26 -3,34% 6,18% 49.733
25/09/2003 34,20 35,22 31,50 32,34 -5,77% 10,88% 60.583
24/09/2003 36,12 36,60 34,32 34,32 -5,30% 6,31% 76.000
23/09/2003 34,20 36,90 33,84 36,24 +5,04% 8,95% 116.217
22/09/2003 34,50 35,46 33,78 34,50 -1,88% 4,87% 45.533
19/09/2003 35,40 36,24 34,26 35,16 -2,17% 5,59% 72.650